sana semaglutide for Non-Diabetics: A Guide to Weight Loss with GLP-1 in Dallas A promising new approach to
Description
In the latest JAMA Medical News podcast, Jennifer Abbasi interviews Rita Kalyani, MD, about investigational therapies including retatrutide, a triple agonist showing high efficacy for glycemic control and weight loss, and new oral options like orforglipron
2 The primary outcome included the time to first occurrence of MACE from week zero up to 61 months or more
The most common side effects reported in retatrutide trials are nausea, vomiting, diarrhea, and constipation
Stimulant medications can increase heart rate and blood pressure, while GLP-1 medications also affect cardiovascular function in some users
doi: 10.1002/jgh3.12780
